Arrowhead Pharmaceuticals, Inc. ARWR
Regular-session close
After hours · Nov 20, 4:09 PM ET
- YTD
- -37.69%
- 1 year
- +8.61%
5D -4.90 (-10.44%)
- Market cap
- 5.85B
- Revenue (ttm)
- 450.82M
- Profit margin
- -160.64%
- EPS (ttm)
- -5.11
- Shares out
- 141.37M
- Forward P/E
- -11.22
- YTD return
- -37.69%
- 1-year return
- +8.61%
- 50-day average
- 60.07
- 200-day average
- 70.54
- Volume
- 3.91M
- Avg volume
- 2.04M
- Open
- 43.42
- Previous close
- 43.65
- Day's range
- 41.17 – 44.80
- 52-week range
- 38.09 – 89.59
- Beta
- 1.37
- Analysts
- Strong Buy
- Price target
- 105.86 (+155.9%)
- Earnings date
- Feb 4, 2027
Key statistics
- Enterprise value
- 6.39B
- Price / sales
- 12.97
- Price / book
- 116.21
- Revenue growth
- -85.30%
- Free cash flow
- -587.00M
- Total cash
- 1.19B
- Total debt
- 1.41B
- Return on equity
- -258.93%
- Short % of float
- 11.40%
Fundamental scorecard
4 of 25 checks passed on ARWR’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 73.00
- Target (mean)
- 105.86
- Target (high)
- 126.00
- Strong buy4
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate -1.79.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | -1.45 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | -1.52 | -3.04 | -1.52 | -100.00% |
| Aug 4, 2026 | Jun 30, 2026 | -1.28 | -1.36 | -0.08 | -6.25% |
| May 7, 2026 | Mar 31, 2026 | -1.09 | -0.93 | +0.16 | +14.68% |
| Feb 5, 2026 | Dec 31, 2025 | 0.60 | 0.22 | -0.38 | -63.33% |
| Nov 25, 2025 | Sep 30, 2025 | -0.11157 | -0.18 | -0.07 | -61.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 17, 2026 | Citigroup | main | Buy | Buy |
| Nov 13, 2026 | RBC Capital | reit | Outperform | Outperform |
| Nov 13, 2026 | Stifel | main | Buy | Buy |
| Oct 15, 2026 | Chardan Capital | main | Buy | Buy |
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 8, 2026 | Citigroup | init | — | Buy |
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; Novartis Pharma AG; Madrigal Pharmaceuticals, Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arrowheadpharma.com
News
Arrowhead Pharmaceuticals Eyes $3 Billion REDEMPLO Opportunity as FDA Review Looms
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Citigroup Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $105
94,000 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR Bought by ACT Capital Partners L.P. RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target
Stifel Maintains Buy on Arrowhead Pharma, Lowers Price Target to $96
Arrowhead Pharma Q4 EPS $(3.01) Misses $(1.61) Estimate, Sales $37.794M Miss $55.838M Estimate
Cisco Systems, Applied Materials On Deck Thursday As AI Demand Faces Test
Nasdaq 100 Jumps 3% as Chips Rebound; Nvidia Lags Most Since DeepSeek: Stock Market Today
Your note
Sign in to keep a note on ARWR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANZALONE CHRISTOPHER RICHARD | Chief Executive Officer | Sale | Jan 1, 2026 | 3,792,740 |
| APEL DANIEL JOSEPH | Chief Financial Officer | Sale | Apr 21, 2026 | 162,905 |
| FERRARI MAURO | Director | Sale | Dec 25, 2025 | 69,053 |
| GIVEN DOUGLAS BRUCE | Director | Sale | Dec 16, 2024 | 124,167 |
| HAMILTON JAMES C | Officer | Sale | Apr 22, 2026 | 226,958 |
| LU HONGBO B | Director | Sale | May 11, 2026 | 52,012 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.71% | 15,140,840 | 626.38M | Sep 29, 2026 |
| Avoro Capital Advisors LLC | 7.78% | 11,000,000 | 455.07M | Sep 29, 2026 |
| FMR, LLC | 6.62% | 9,355,747 | 387.05M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.39% | 6,210,955 | 256.95M | Sep 29, 2026 |
| State Street Corporation | 4.33% | 6,122,271 | 253.28M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.33% | 6,118,719 | 253.13M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 5,031,501 | 208.15M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.00% | 4,246,637 | 175.68M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.17% | 3,067,819 | 126.92M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.88% | 2,663,269 | 110.18M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.27% | 1,788,396 | 73.99M | Sep 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Momentum ETF | 1.27% | 1,799,303 | 74.44M | Sep 29, 2026 |
